ataciguat (HMR1766) + placebo + cilostazol

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Intermittent Claudication

Conditions

Intermittent Claudication

Trial Timeline

Feb 1, 2007 → Oct 1, 2008

NCT ID

NCT00443287

About ataciguat (HMR1766) + placebo + cilostazol

ataciguat (HMR1766) + placebo + cilostazol is a phase 2 stage product being developed by Sanofi for Intermittent Claudication. The current trial status is completed. This product is registered under clinical trial identifier NCT00443287. Target conditions include Intermittent Claudication.

What happened to similar drugs?

1 of 2 similar drugs in Intermittent Claudication were approved

Approved (1) Terminated (1) Active (0)

✅Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved

❌Azithromycin plus chloroquine + sulfadoxine-pyrimethaminePfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00443287	Phase 2	Completed	Feb 1, 2007	Oct 1, 2008	Intermittent Claudication

Competing Products

12 competing products in Intermittent Claudication

See all competitors

Product	Company	Stage	Hype Score
Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg	AstraZeneca	Approved	43
LLG783 + Placebo	Novartis	Phase 2	35
Azithromycin plus chloroquine + sulfadoxine-pyrimethamine	Pfizer	Phase 3	32
Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16	Sanofi	Phase 2	35
SL650472, Clopidogrel	Sanofi	Phase 2	35
Givosiran	Alnylam Pharmaceuticals	Phase 1/2	29
Givosiran + 5-probe cocktail	Alnylam Pharmaceuticals	Phase 1	26
givosiran (ALN-AS1) + Sterile Normal Saline (0.9% NaCl)	Alnylam Pharmaceuticals	Phase 1	26
Sapropterin Dihydrochloride	BioMarin Pharmaceutical	Phase 2	32
Tetrahydrobiopterin 10 mg/kg + Tetrahydrobiopterin 20 mg/kg + L-Ascorbate + L-Arginine	BioMarin Pharmaceutical	Phase 1	33
Placebo + 375 mg CK-2017357 + 500 mg CK-2017357	Cytokinetics	Phase 2	32
Pimavanserin 34 mg + Placebo	Acadia Pharmaceuticals	Phase 2	39